Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 289 participants.

Also called NCT05085275

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 289 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05085275
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05085275. Randomized; quadruple masking; primary purpose treatment. Start 2022-03-30 (actual); primary completion 2024-01-24 (actual). Results posted on 2025-08-29.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease
Acronym
FRONTIER
Condition
Anemia, Iron Deficiency
Condition
Hyperphosphatemia
Condition
Renal Insufficiency, Chronic
Condition
Renal Anemia
Condition
Disease Progression
Condition
Cardiovascular
Condition
Iron
Intervention (Drug)
Ferric Citrate 1 GM Oral Tablet [AURYXIA]
Intervention (Drug)
Placebo
Lead sponsor
USRC Kidney Research (class: research network)
Collaborator
Akebia Therapeutics (class: industry)

Record details

Record id
cardio:ct-nct05085275
Content hash
bbf699bdeac42defffcc2bedf26ad0b24d107b96c7b991a9947ced3d479d27b9